Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cyanonitrosylferrate
2. Disodium Salt Nitroprusside
3. Ketostix
4. Naniprus
5. Nipride
6. Nipruton
7. Nitriate
8. Nitropress
9. Nitroprussiat Fides
10. Nitroprusside
11. Nitroprusside, Disodium Salt
12. Nitroprusside, Disodium Salt, Dihydrate
13. Nitroprusside, Sodium
14. Sodium Nitroprusside
1. 15078-28-1
2. Pentacyanidonitrosylferrate(2-)
3. Iron(4+);nitroxyl Anion;pentacyanide
4. Pentacyano(nitroso)iron(2-)
5. Chebi:7596
6. Pentacyanidonitrosylferrate(iii)
7. [fe(cn)5(no)](2-)
8. Bdbm50377921
9. Db00325
10. Ncgc00166055-01
11. Ncgc00166055-04
12. Sbi-0206675.p002
13. C07269
14. Ab00920709_03
15. Ferrate(2-), Pentakis(cyano-.kappa.c)-nitrosyl
1. Nitroprusside Sodium
2. Nitroprusside Sodium Dihydrate
Molecular Weight | 215.94 g/mol |
---|---|
Molecular Formula | C5FeN6O-2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 0 |
Exact Mass | 215.948294 g/mol |
Monoisotopic Mass | 215.948294 g/mol |
Topological Polar Surface Area | 137 Ų |
Heavy Atom Count | 13 |
Formal Charge | -2 |
Complexity | 119 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 7 |
For immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure
Nitroprusside a powerful vasodilator relaxes the vascular smooth muscle and produce consequent dilatation of peripheral arteries and veins. Other smooth muscle (e.g., uterus, duodenum) is not affected. Sodium nitroprusside is more active on veins than on arteries.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Indicators and Reagents
Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh's Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)
Nitric Oxide Donors
A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81) (See all compounds classified as Nitric Oxide Donors.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Route of Elimination
One molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN ions, thiosulfate reacts with cyanide to produce thiocyanate, thiocyanate is eliminated in the urine.
Metabolized by reaction with hemoglobin to produce cyanmethemoglobin and cynide ions
Approximately 2 minutes
One molecule of sodium nitroprusside is metabolized by combination with hemoglobin to produce one molecule of cyanmethemoglobin and four CN- ions; methemoglobin, obtained from hemoglobin, can sequester cyanide as cyanmethemoglobin; thiosulfate reacts with cyanide to produce thiocyanate; thiocyanate is eliminated in the urine; cyanide not otherwise removed binds to cytochromes. Cyanide ion is normally found in serum; it is derived from dietary substrates and from tobacco smoke. Cyanide binds avidly (but reversibly) to ferric ion (Fe+++), most body stores of which are found in erythrocyte methemoglobin (metHgb) and in mitochondrial cytochromes. When CN is infused or generated within the bloodstream, essentially all of it is bound to methemoglobin until intraerythrocytic methemoglobin has been saturated. Sodium nitroprusside is further broken down in the circulation to release nitric oxide (NO), which activates guanylate cyclase in the vascular smooth muscle. This leads to increased production of intracellular cGMP, which stimulates calcium ion movement from the cytoplasm to the endoplasmic reticulum, reducing the level of available calcium ions that can bind to calmodulin. This ultimately results in vascular smooth muscle relaxation and vessel dilation.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
13
PharmaCompass offers a list of Sodium Nitroprusside API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Nitroprusside manufacturer or Sodium Nitroprusside supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Nitroprusside manufacturer or Sodium Nitroprusside supplier.
PharmaCompass also assists you with knowing the Sodium Nitroprusside API Price utilized in the formulation of products. Sodium Nitroprusside API Price is not always fixed or binding as the Sodium Nitroprusside Price is obtained through a variety of data sources. The Sodium Nitroprusside Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nipruss manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nipruss, including repackagers and relabelers. The FDA regulates Nipruss manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nipruss API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nipruss manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nipruss supplier is an individual or a company that provides Nipruss active pharmaceutical ingredient (API) or Nipruss finished formulations upon request. The Nipruss suppliers may include Nipruss API manufacturers, exporters, distributors and traders.
click here to find a list of Nipruss suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nipruss DMF (Drug Master File) is a document detailing the whole manufacturing process of Nipruss active pharmaceutical ingredient (API) in detail. Different forms of Nipruss DMFs exist exist since differing nations have different regulations, such as Nipruss USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nipruss DMF submitted to regulatory agencies in the US is known as a USDMF. Nipruss USDMF includes data on Nipruss's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nipruss USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nipruss suppliers with USDMF on PharmaCompass.
A Nipruss CEP of the European Pharmacopoeia monograph is often referred to as a Nipruss Certificate of Suitability (COS). The purpose of a Nipruss CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nipruss EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nipruss to their clients by showing that a Nipruss CEP has been issued for it. The manufacturer submits a Nipruss CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nipruss CEP holder for the record. Additionally, the data presented in the Nipruss CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nipruss DMF.
A Nipruss CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nipruss CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nipruss suppliers with CEP (COS) on PharmaCompass.
A Nipruss written confirmation (Nipruss WC) is an official document issued by a regulatory agency to a Nipruss manufacturer, verifying that the manufacturing facility of a Nipruss active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nipruss APIs or Nipruss finished pharmaceutical products to another nation, regulatory agencies frequently require a Nipruss WC (written confirmation) as part of the regulatory process.
click here to find a list of Nipruss suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nipruss as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nipruss API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nipruss as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nipruss and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nipruss NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nipruss suppliers with NDC on PharmaCompass.
Nipruss Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nipruss GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nipruss GMP manufacturer or Nipruss GMP API supplier for your needs.
A Nipruss CoA (Certificate of Analysis) is a formal document that attests to Nipruss's compliance with Nipruss specifications and serves as a tool for batch-level quality control.
Nipruss CoA mostly includes findings from lab analyses of a specific batch. For each Nipruss CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nipruss may be tested according to a variety of international standards, such as European Pharmacopoeia (Nipruss EP), Nipruss JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nipruss USP).